Lynk Solutec has been officially designated as an Innovative Product by the Public Procurement Service (PPS), marking a significant milestone for the company’s entry into the public procurement market and the expansion of its technology commercialization. This designation represents national recognition of the company’s technological capabilities and innovation.

The designated product is C.E.V. (Innovative Product Name: Endoscope Connector for Securing Clear Vision), a medical device component designed to prevent contamination from bodily fluids and foreign substances during endoscopic procedures, while ensuring clear visibility. Powered by Lynk Solutec’s proprietary coating technology, the product enhances procedural efficiency for medical professionals and improves patient safety.

This recognition is expected to strengthen Lynk Solutec’s competitiveness in the public procurement market while creating new opportunities for collaboration with medical and public institutions.

Moving forward, Lynk Solutec will continue to advance next-generation coating technologies and drive consistent quality innovation, with the goal of delivering tailored coating solutions optimized for clinical applications both domestically and globally.

Lynk Solutec Inc. participated in the “Lab-Thursday Talk” program hosted by Ewha Womans University Medical Center, presenting its latest medical coating technologies. The session was led by Dr. Yeontack Lee, CEO of Lynk Solutec, who introduced the company’s innovative coating solutions, their applications in medical devices, and potential directions for future collaborative research.

Lab-Thursday Talk is a regular program designed to foster collaboration between clinical and basic researchers and industry partners. Having been held more than 30 times, it has become a key platform for sharing research expertise and exploring opportunities for joint R&D projects.

Through this presentation, Lynk Solutec highlighted the innovation of its endoscopic coating technology and other medical device applications, while seeking opportunities for clinical collaboration and co-development. Moving forward, the company will continue to strengthen its research and development capabilities, expand its collaboration network with domestic and international medical institutions, and provide optimized coating solutions tailored to clinical needs.

Lynk Solutec has completed a U.S. patent application for its proprietary endoscopic coating technology, marking a significant milestone in the company’s efforts to expand into the global medical device market. This application follows the company’s domestic patent for its anti-fogging endoscopic coating agent and specialized certification, further validating the global applicability of Lynk Solutec’s innovative technology.

With this U.S. patent application, the company’s “Lynk Coating” technology has gained greater potential for adoption in the international medical device arena. Lynk Solutec plans to actively pursue global market expansion and technology licensing opportunities based on this advancement. The technology offers a groundbreaking solution that enhances surgical visibility and prevents the adhesion of biological substances, ultimately improving both procedural efficiency for medical professionals and safety for patients.

Looking ahead, Lynk Solutec aims to continue its growth in the global healthcare market through the development of next-generation coating technologies. The company is also committed to securing additional international certifications and strengthening global partnerships to ensure its solutions are widely adopted across diverse medical environments worldwide.

Lynk Solutec, a medical device surface coating technology company led by CEO Jungmok Seo, has announced the acquisition of two innovative coating technology patents that can significantly enhance safety in medical settings. The newly registered patents are for “Medical Implant Coating Composition for Foreign Material Prevention” and “Suture Coating Composition for Foreign Material Prevention.”

The core of these newly developed coating technologies lies in their special composition that fundamentally prevents the adhesion of all foreign materials, including blood, moisture, mucus, and bacteria. CTO Yeonteak Lee explained, “Medical implants and sutures come into contact with various foreign substances within the body, such as blood, mucus, bacteria, cells, and calcification. The adhesion of these substances can cause serious side effects, including infections, inflammation, and thrombosis formation. These patent technologies provide an innovative solution that fundamentally addresses these issues.”

The implant coating technology can be applied to a wide range of medical devices, including various types of stents for the esophagus, blood vessels, bile duct, gallbladder, pancreas, uterus, urethra, and ureter, as well as drainage catheters, injection catheters, parenteral catheters, and urological catheters. The suture coating technology is applicable to all types of sutures, including dental/ophthalmic and microsurgical sutures. Notably, unlike existing coating technologies, these new innovations allow for additional lubricant coating on top of the coated medical devices, further enhancing their performance.

CEO Jungmok Seo emphasized, “These patent technologies can dramatically reduce medical device-related complications. In particular, they can significantly improve the safety and accuracy of surgical procedures by minimizing the risks of infection, inflammation, and thrombosis formation.” He also added, “We are currently preparing for clinical trials to commercialize these patent technologies and plan to complete product development in the near future.”

Lynk Solutec, a spin-off company from the BioLogical Interfaces and Sensor Systems Laboratory at Yonsei University, continues to drive innovation in medical settings through its medical device coating technologies.

Jung-mok Seo, CEO of Lynk Solutec, a company developing innovative medical devices based on medical device coating technology, was invited as a speaker at the 2024 Yonsei University Laboratory Startup Conference.

During the event, CEO Seo presented successful cases of technology startups as a professor in the Department of Electrical and Electronic Engineering. Leading the Yonsei University BioLogical Interface and Sensor Systems Laboratory, he developed a coating technology that can fundamentally inhibit infection, inflammation, and thrombosis for the first time in the world. He shared vibrant examples of how he is expanding his business by showcasing innovative medical devices such as “an endoscopic cap that provides a clear surgical view” and “a ureteral stent that inhibits calcification”

In the following “Laboratory Startup Talk Concert,” he participated in a panel discussion with the Yonsei University Startup Support Team. CEO Seo shared insights on the development direction and challenges of the laboratory startup ecosystem, drawing significant interest from the audience.